Alessandro Russo, Medical Oncologist and Assistant Professor at Humanitas Clinical Institute of Catania, shared a post on X:
”Out now on Annals of Oncology our editorial commenting the results of the study of Mihaela Aldea on the frequency and therapeutic relevance of MTAP loss in AGA+ NSCLC.
Thanks to my friend Umberto Malapelle for involving me to discuss such relevant topic!”
Title: PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?
Authors: Umberto Malapelle, Alessandro Russo
Other Articles Featuring Alessandro Russo On OncoDaily.